

Literaturliste zum Artikel MMW-Fortschr.Med. Nr. 37/2004 (146. Jg.):

## **Ausschluss einer Herzinsuffizienz bei akuter Dyspnoe: Was bringt ein Schnelltest in der täglichen Praxis?**

St. Finsterer, Ch. Nentwich, S. Silber

1. Pfeffer, M.A., et al., *Valsartan in acute myocardial infarction trial (VALIANT): rationale and design*. Am Heart J, 2000. **140**(5): p. 727-50.
2. Maisel, A.S., et al., *Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure*. N Engl J Med, 2002. **347**(3): p. 161-7.
3. McCullough, P.A., et al., *B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study*. Circulation, 2002. **106**(4): p. 416-22.
4. Bayes-Genis, A., et al., *N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction*. Eur J Heart Fail, 2004. **6**(3): p. 301-8.
5. Maisel, A., *B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next?* Circulation, 2002. **105**(20): p. 2328-31.
6. de Lemos, J.A., et al., *The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes*. N Engl J Med, 2001. **345**(14): p. 1014-21.
7. Sagnella, G.A., *Measurement and significance of circulating natriuretic peptides in cardiovascular disease*. Clin Sci (Lond), 1998. **95**(5): p. 519-29.
8. Stein, B.C. and R.I. Levin, *Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease*. Am Heart J, 1998. **135**(5 Pt 1): p. 914-23.
9. Wang, T.J., et al., *Plasma natriuretic peptide levels and the risk of cardiovascular events and death*. N Engl J Med, 2004. **350**(7): p. 655-63.
10. Cheng, V., et al., *A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study*. J Am Coll Cardiol, 2001. **37**(2): p. 386-91.
11. Maeda, K., et al., *High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure*. J Am Coll Cardiol, 2000. **36**(5): p. 1587-93.
12. Troughton, R.W., et al., *Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations*. Lancet, 2000. **355**(9210): p. 1126-30.

13. Sudoh, T., et al., *A new natriuretic peptide in porcine brain*. Nature, 1988. **332**(6159): p. 78-81.
14. Yasue, H., et al., *Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure*. Circulation, 1994. **90**(1): p. 195-203.
15. Stanek, B., *BNP Testing in Heart Failure-One Fits All?* J Clin Basic Cardiol, 2003. **6** (1-4): p. 15-8.
16. Levin, E.R., D.G. Gardner, and W.K. Samson, *Natriuretic peptides*. N Engl J Med, 1998. **339**(5): p. 321-8.
17. Hunt, P.J., et al., *Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment*. Clin Endocrinol (Oxf), 1997. **47**(3): p. 287-96.
18. Luchner, A., et al., *Bedeutung der Herzinsuffizienzmarker BNP und NT-proBNP für die Klinik*. Deutsches Ärzteblatt, 2003. **100**(50): p. 3314-3321.
19. Wei, C.M., et al., *Natriuretic peptide system in human heart failure*. Circulation, 1993. **88**(3): p. 1004-9.
20. Lerman, A., et al., *Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction*. Lancet, 1993. **341**(8853): p. 1105-9.
21. Cowie, M.R., et al., *Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care*. Lancet, 1997. **350**(9088): p. 1349-53.
22. Campbell, D.J., et al., *Plasma amino-terminal pro-brain natriuretic peptide: a novel approach to the diagnosis of cardiac dysfunction*. J Card Fail, 2000. **6**(2): p. 130-9.
23. Pfister, R., et al., *Use of NT-proBNP in routine testing and comparison to BNP*. Eur J Heart Fail, 2004. **6**(3): p. 289-93.
24. Maisel, A., *B-Type Natriuretic Peptide (BNP) Levels: Diagnostic and Therapeutic Potential*. MedReviews, 2001. **2**(suppl 2): p. 13-18.
25. Redfield, M.M., et al., *Plasma brain natriuretic peptide concentration: impact of age and gender*. J Am Coll Cardiol, 2002. **40**(5): p. 976-82.
26. Nagaya, N., et al., *Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension*. J Am Coll Cardiol, 1998. **31**(1): p. 202-8.
27. Latini, R., et al., *Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT)*. Circulation, 2002. **106**(19): p. 2454-8.
28. Lubien, E., et al., *Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings*. Circulation, 2002. **105**(5): p. 595-601.

29. Maisel, A.S., et al., *Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction*. Am Heart J, 2001. **141**(3): p. 367-74.
30. Dao, Q., et al., *Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting*. J Am Coll Cardiol, 2001. **37**(2): p. 379-85.
31. McDonagh, T.A., et al., *NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies*. Eur J Heart Fail, 2004. **6**(3): p. 269-73.
32. Mueller, C. and P. Buser, *B-type natriuretic peptide (BNP): can it improve our management of patients with congestive heart failure?* Swiss Med Wkly, 2002. **132**(43-44): p. 618-22.
33. Maisel, A.S., et al., *Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study*. J Am Coll Cardiol, 2003. **41**(11): p. 2010-7.
34. Remme, W.J. and K. Swedberg, *Guidelines for the diagnosis and treatment of chronic heart failure*. Eur Heart J, 2001. **22**(17): p. 1527-60.
35. Mair, J., et al., *Natriuretic peptides in assessment of left-ventricular dysfunction*. Scand J Clin Lab Invest Suppl, 1999. **230**: p. 132-42.
36. Tapanainen, J.M., et al., *Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era*. J Am Coll Cardiol, 2004. **43**(5): p. 757-63.
37. Hartmann, F., et al., *NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy*. Eur J Heart Fail, 2004. **6**(3): p. 343-50.

Für die Autoren:

Prof. Dr. med. Sigmund Silber

F.A.C.C., F.E.S.C

Kardiologische Praxis und Praxisklinik

Am Isarkanal 36

81379 München

Tel: 089-74215130

Fax: 089-74215131

[silber@med.de](mailto:silber@med.de)

[www.sigmund-silber.com](http://www.sigmund-silber.com)